Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1856448 | 1.00 | NPY5R (0.59) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL1107401 | 0.86 | NPY5R (0.70) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL2645649 | 0.86 | NPY5R (0.70) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL8153290 | 0.85 | NPY5R (0.78) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL31106918 | 0.82 | GAA (0.51) | NPY5RGAAALDH1A1KDM4EAOC3 | |
| SCHEMBL1861747 | 0.81 | NPY5R (0.60) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL1861749 | 0.81 | NPY5R (0.60) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL2645267 | 0.81 | NPY5R (0.60) | NPY5RGAAALDH1A1KDM4EOPRK1 | |
| SCHEMBL1865464 | 0.81 | NPY5R (0.58) | NPY5RGAAALDH1A1OPRK1CYP2D6 | |
| SCHEMBL1865463 | 0.81 | NPY5R (0.58) | NPY5RGAAALDH1A1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | NPY5R 2934/4885GAA 150/4885ALDH1A1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.